Pharmacodynamics of peg-ifn alpha-2a and hcv response as a function of il28b polymorphism in hiv/hcv co-infected patients (2010)
- Authors:
- Autor USP: BARONE, ANTONIO ALCI - FM
- Unidade: FM
- Subjects: HOSPEDEIRO IMUNOCOMPROMETIDO; INFECÇÕES POR HIV; FARMACODINÂMICA; RESUMOS (EVENTOS); HEPATITE C (VIROLOGIA); HEPATITE VIRAL HUMANA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Hepatology
- ISSN: 0270-9139
- Volume/Número/Paginação/Ano: v. 52, n. 4 (suppl), p. 750A, res. 896, 2010
-
ABNT
ARAÚJO, Evaldo S.; DAHARI, Harel; COTLER, Scott J.; et al. Pharmacodynamics of peg-ifn alpha-2a and hcv response as a function of il28b polymorphism in hiv/hcv co-infected patients. Hepatology[S.l: s.n.], 2010. -
APA
Araújo, E. S., Dahari, H., Cotler, S. J., Layden, T. J., Neumann, A. U., Melo, C. E., & Barone, A. A. (2010). Pharmacodynamics of peg-ifn alpha-2a and hcv response as a function of il28b polymorphism in hiv/hcv co-infected patients. Hepatology. Baltimore. -
NLM
Araújo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA. Pharmacodynamics of peg-ifn alpha-2a and hcv response as a function of il28b polymorphism in hiv/hcv co-infected patients. Hepatology. 2010 ; 52( 4 (suppl): 750A. -
Vancouver
Araújo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA. Pharmacodynamics of peg-ifn alpha-2a and hcv response as a function of il28b polymorphism in hiv/hcv co-infected patients. Hepatology. 2010 ; 52( 4 (suppl): 750A. - Weigt-based combination therapy with peginterferon alfa 2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C
- Patients with chronic hepatitis C and normal transaminases
- Lesoes encefalicas cryptococcus neofarmans em um paciente com AIDS
- Effect of the technique of 'semen washing' in the removal of the hepatitis C virus in infected patients
- The importance of the HCV-NS4 peptide for the definition of serological types of hepatitis C virus
- Peginterferon A-2B plus ribavirin in relapser and mon-responder Brazilian HCV patients
- Imunopatogênese
- 72 weeks treatment duration reduces relapse rate in hcv/hiv co-infected patients with end of treatment response
- Pharmacodynamics of PEG-IFN-ALFA-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients
- Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the anteretroviral therapy received
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
